Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917419 | 0.84 | STS (0.49) | CYP2B6CYP1A2CYP1B1STSMAPT | |
| SCHEMBL3199320 | 0.80 | AHR (0.45) | CYP2B6CYP1A2CYP1B1STSMAPT | |
| SCHEMBL4550984 | 0.76 | CYP2B6 (0.46) | CYP2B6CYP1A2CYP1B1STSCA9 | |
| SCHEMBL5545197 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A2CYP1B1STSCA9 | |
| SCHEMBL5390733 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A2CYP1B1STSCA9 | |
| SCHEMBL18617980 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A2CYP1B1STSCA9 | |
| SCHEMBL2007996 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A2CYP1B1STSCA9 | |
| SCHEMBL1192912 | 0.76 | CYP3A4 (0.45) | CYP2B6CYP1A2CYP1B1STSMAPT | |
| SCHEMBL277261 | 0.76 | CYP2B6 (0.46) | CYP2B6CYP1A2CYP1B1STSCA9 | |
| SCHEMBL6957005 | 0.76 | CA1 (0.44) | CYP2B6CYP1A2CYP1B1STSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3582783-B1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-9776967-B2 | Carboxamide derivatives as pesticidal compounds | BAYER ANIMAL HEALTH GMBH (DE) | 2017-10-03 | — | — | US | disclosed |
| US-20170210725-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2017-07-27 | — | — | US | disclosed |
| WO-2017105999-A1 | N-[[5-[[[1-(PHENYL)ETHYLIDENE]AMINO]OXY]PHENYL]-METHYL]CARBAMATE DERIVATIVES AND RELATED COMPOUNDS AS FUNGICIDES FOR CONTROLLING PLANT DISEASES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017040545-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20160221950-A1 | CARBOXAMIDE DERIVATIVES AS PESTICIDAL COMPOUNDS | ELANCO ANIMAL HEALTH GMBH (DE) | 2016-08-04 | — | — | US | disclosed |
| WO-2016049586-A2 | NON-BETA LACTAM ANTIBIOTICS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-9290487-B2 | Pharmaceutical composition for treating diabetes | AJINOMOTO CO., INC. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-8921360-B2 | Heterobicycle-substituted azolyl benzene fungicides | E. I. DU PONT DE NEMOURS AND COMPANY | 2014-12-30 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | WANG SHAOMENG (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011059619-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| EP-0936211-B1 | Aryl-acrylic acid esters useful as precursors for organoleptic compounds | GIVAUDAN SA (CH) | 2010-07-07 | — | — | EP | disclosed |
| CN-1289460-C | Aryl-acrylic acid esters | GIVAUDAN ROURE INTERNAT S A (CH) | 2006-12-13 | — | — | CN | disclosed |
| US-6096918-A | USEFUL FOR THE DELIVERY OF ORGANOLEPTIC COMPOUNDS, ESPECIALLY FOR FLAVORS, FRAGRANCES, MASKING AGENTS AND ANTIMICROBIAL COMPOUNDS. THEY CAN ALSO DELIVER FLUORESCENT WHITENING AGENTS. | GIVAUDAN ROURE (INTERNATIONAL) SA (CH) | 2000-08-01 | — | — | US | disclosed |
| CN-1227837-A | Aryl-acrylic acid esters | GIVAUDAN ROURE INT (CH) | 1999-09-08 | — | — | CN | disclosed |
| EP-0936211-A2 | Aryl-acrylic acid esters useful as precursors for organoleptic compounds | Givaudan Roure (International) S.A. (CH) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210725-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | CYP2B6 388/4885CYP1A2 686/4885CYP1B1 421/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | CYP2B6 1176/4885CYP1A2 1924/4885CYP1B1 1995/4885 |
| US-20160221950-A1 | CARBOXAMIDE DERIVATIVES AS PESTICIDAL COMPOUNDS | ACHE, DDT, NIT2 | CYP2B6 563/4885CYP1A2 152/4885CYP1B1 622/4885 |
| US-20110319362-A1 | STAT3 LIGANDS AND THERAPEUTIC USES THEREOF | STAT3, JAK2, STAT6 | CYP2B6 4287/4885CYP1A2 4602/4885CYP1B1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.